Last reviewed · How we verify

DOCETAXEL(XRP6976) + MODAFINIL

Sanofi · Phase 3 active Small molecule

Docetaxel stabilizes microtubules to inhibit cancer cell division, while modafinil enhances wakefulness and may improve treatment tolerability and cognitive function during chemotherapy.

Docetaxel stabilizes microtubules to inhibit cancer cell division, while modafinil enhances wakefulness and may improve treatment tolerability and cognitive function during chemotherapy. Used for Advanced or metastatic solid tumors (Phase 3 investigational), Cancer-related fatigue and cognitive impairment during chemotherapy.

At a glance

Generic nameDOCETAXEL(XRP6976) + MODAFINIL
SponsorSanofi
Drug classTaxane chemotherapy + wakefulness-promoting agent combination
Targetβ-tubulin (docetaxel); dopamine/norepinephrine/histamine systems (modafinil)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Docetaxel is a taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Modafinil is a wakefulness-promoting agent that acts on multiple neurotransmitter systems (dopamine, norepinephrine, histamine) to combat chemotherapy-induced fatigue and cognitive impairment, potentially improving patient compliance and quality of life during treatment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: